About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase I/II Combination With Irinotecan- Erbitux

NCT00594984·12 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bristol-Myers Squibb

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Biopsy proven MCRC
Prior irinotecan allowed
Prior Erbitux allowed

You may not be if

No prior brivanib
No prior combination of irinotecan with Erbitux
No secondary malignancies
No anti-coagulation therapy
No prior history of blood clots requiring anti-coagulation

The record

StatusCompleted

PhasePhase 1–2

Taking part38

StartedMay 2008

UpdatedNov 4, 2015

Conditions

Metastatic Colorectal Cancer (MCRC)

Where12

Usc/Norris Comprehensive Cancer Center Hospital
Los Angeles, California, United States
Usc/Norris Comprehensive Cancer Center
Los Angeles, California, United States
James Graham Brown Cancer Center
Louisville, Kentucky, United States

Clareo Health | Phase I/II Combination With Irinotecan- Erbitux